mail
versión imprimible
 
 

4th Annual RAS Targeted Drug Development Summit

Evvnt Promotion / evvnt
-
26.09.2022 - 28.09.2022  Boston Marriott Burlington, One Burlington Mall Road, 01803 Burlington, Massachusetts, USA
Time: 8:30 AM - 6:00 PM
 
Temas de la conferencia
For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is in fact druggable and that drugging this protein unlocks a world of successful therapeutic interventions. Now, the future looks bright for treating patients with cancers harboring the RAS mutation.
Organizador profesional (PCO)
Hanson Wade
 

Información e inscripción:

https://go.evvnt.com/1209735-2?pid=4832
Ms. Erin Thomas
 
Categorías
Medicina General
Idioma
Inglés
Cuota del Congreso
USD 2599.00 - USD 5398.00
Los participantes esperaban
1000
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."

Anästhesie in Entwicklungsländern e. V.OÖ Gebietskrankenkasse, Referat für Wissenschaftskooperation Helix - Forschung & Beratung WienÄrztekammer für WienÖsterreichische Akademie der ÄrzteAlumni Club Medizinische Universität WienEuropean Public Health Association (EUPHA)AGEM - Arbeitsgemeinschaft Ethnologie und Medizin